Matthew H. Wilson, MD, PhD, is a physician-scientist nephrologist and a Professor of Medicine in the Division of Nephrology and Hypertension within the Department of Medicine at Vanderbilt University Medical Center. He completed internal medicine residency and fellowship in nephrology at Vanderbilt. He began his career at Baylor College of Medicine as an Assistant Professor focused on cell and gene therapy use of the non-viral piggyBac transposon system. He has successfully developed and implemented its use for gene transfer in vivo in animal models and to human cells including human T cells. This work has laid the foundation for clinical trials in the U.S. and around the world and may open recently approved chimeric antigen T cell therapy for cancer to more patients worldwide. Dr. Wilson has served on the board of directors of the American Society of Gene and Cell Therapy and is a member of the American Society of Nephrology. He has spoken at national and international academic conferences on his work in gene transfer. His laboratory funded by the NIH and VA has been engineering cell and gene transfer for kidney disease and its complications by translating this technology to address critical barriers of therapy in animal models of kidney disease. His recent work has led to patents related to using T cells as vehicles for therapeutic proteins, engineering a cell therapy for kidney disease via regenerative medicine, and next-generation transpososomes for genome engineering. Dr. Wilson is an elected member of the American Society for Clinical Investigation and has received a Senior Clinician Scientist Investigator Award from the Department of Veterans Affairs. Dr. Wilson is a practicing internal medicine physician and nephrologist at the Nashville VA hospital.